Ticker
ABOS

Price
6.57
Stock movement up
+1.24 (23.26%)
Company name
Acumen Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
268.88M
Ent value
117.95M
Price/Sales
-
Price/Book
1.37
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
31.14%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2023-01-31

DIVIDENDS

ABOS does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book1.37
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count40.93M
EPS (TTM)-0.95
FCF per share (TTM)-0.69

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-39.40M
Net income (TTM)-38.34M
EPS (TTM)-0.95
EPS (1y forward)-1.22

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash157.54M
Net receivables121.00K
Total current assets202.56M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets203.26M
Accounts payable2.08M
Short/Current long term debt133.00K
Total current liabilities6.61M
Total liabilities6.61M
Shareholder's equity196.65M
Net tangible assets196.65M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-27.59M
Capital expenditures (TTM)158.00K
Free cash flow (TTM)-27.75M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-19.50%
Return on Assets-18.86%
Return on Invested Capital-19.48%
Cash Return on Invested Capital-14.10%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open5.38
Daily high6.66
Daily low5.35
Daily Volume362K
All-time high20.28
1y analyst estimate15.83
Beta-
EPS (TTM)-0.95
Dividend per share-
Ex-div date-
Next earnings date27 Mar 2023

Downside potential

Loading...
Downside potential data
ABOSS&P500
Current price drop from All-time high-67.60%-14.91%
Highest price drop-84.81%-56.47%
Date of highest drop11 May 20229 Mar 2009
Avg drop from high-60.07%-11.49%
Avg time to new high399 days13 days
Max time to new high398 days1805 days
COMPANY DETAILS
ABOS (Acumen Pharmaceuticals Inc) company logo
Marketcap
268.88M
Marketcap category
Small-cap
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Employees
14
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Here is how Novo Nordisk (NVO) and Acumen Pharmaceuticals, Inc. (ABOS) have performed compared to their sector so far this year.
January 6, 2023
CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
January 4, 2023
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2022 Earnings Call Transcript November 14, 2022 Acumen Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.26 EPS, expectations wer...
December 29, 2022
INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease continues to progress Acumen anticipates completing enrollment in the first quarter of 2023 and reporting to...
November 14, 2022
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel tar...
November 9, 2022
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel tar...
November 7, 2022
Clinical development plan published in Journal of Prevention of Alzheimer’s DiseaseCHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ...
November 1, 2022
CHARLOTTESVILLE, Va. and CARMEL, Ind., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that ACU193, the first clinical-stage monoclonal antibody that sele...
October 24, 2022
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
September 8, 2022
Thank you for standing by, and welcome to the Acumen Pharmaceuticals second quarter 2022 update call. Thank you for joining us today to review Acumen's second quarter 2022 update on operational progr...
August 16, 2022
Next page